Dong-Wan Kim1, Edward B Garon2, Aminah Jatoi3, Dorothy M Keefe4, Mario E Lacouture5, Stephen Sonis6, Diana Gernhardt7, Tao Wang7, Nagdeep Giri8, Jim P Doherty9, Sashi Nadanaciva7, Joseph O'Connell9, Eric Sbar10, Byoung Chul Cho11. 1. Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: kimdw@snu.ac.kr. 2. David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 3. Mayo Clinic, Rochester, MN, USA. 4. University of Adelaide, Adelaide, Australia. 5. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Dana-Farber Cancer Institute, Boston, MA, USA. 7. Pfizer Oncology, Groton, CT, USA. 8. Pfizer Oncology, La Jolla, CA, USA. 9. Pfizer Oncology, New York, NY, USA. 10. Pfizer Oncology, Collegeville, PA, USA. 11. Yonsei University College of Medicine, Seoul, South Korea.
Abstract
OBJECTIVES: Dacomitinib is a pan-HER inhibitor for advanced non-small-cell lung cancer (NSCLC). We explored the impact of a planned 4-day dacomitinib dose interruption on plasma exposure of dacomitinib and adverse events (AEs) of interest in Cohort III of the ARCHER 1042 study. MATERIALS AND METHODS: Patients, treatment-naïve for advanced NSCLC with EGFR activating mutations, received oral dacomitinib 45mg QD (once daily). A planned dose interruption occurred in Cycle 1 from Days 11 through 14. The primary endpoint was the pharmacokinetic (PK) characteristics of dacomitinib in Cycle 1Day 10 and during dose interruption. Secondary endpoints included safety and concomitant medications used to treat AEs of interest. RESULTS: Cohort III enrolled 25 patients. Median plasma Cmax of dacomitinib in Cycle 1 Day 10 was 83.40ng/mL. Average median plasma dacomitinib concentration during the 4-day dose interruption was 42.63ng/mL. In the first 8 weeks of treatment 1) 80% of patients used concomitant medications for dermatologic AEs, 76% for diarrhea, and 44% for stomatitis, and 2) all patients experienced treatment-emergent AEs and 28% had all-causality Grade 3 AEs. CONCLUSION: At 45mg QD dosing, PK parameters of plasma dacomitinib in Cycle 1 Day 10 were comparable to that obtained in Cycle 1 Day 14 from other dacomitinib studies. Average median plasma dacomitinib concentration during the 4-day dose interruption was approximately half of the median plasma Cmax of dacomitinib observed prior to dose interruption. The toxicity profile was consistent with that from other studies of dacomitinib.
OBJECTIVES:Dacomitinib is a pan-HER inhibitor for advanced non-small-cell lung cancer (NSCLC). We explored the impact of a planned 4-day dacomitinib dose interruption on plasma exposure of dacomitinib and adverse events (AEs) of interest in Cohort III of the ARCHER 1042 study. MATERIALS AND METHODS:Patients, treatment-naïve for advanced NSCLC with EGFR activating mutations, received oral dacomitinib 45mg QD (once daily). A planned dose interruption occurred in Cycle 1 from Days 11 through 14. The primary endpoint was the pharmacokinetic (PK) characteristics of dacomitinib in Cycle 1Day 10 and during dose interruption. Secondary endpoints included safety and concomitant medications used to treat AEs of interest. RESULTS: Cohort III enrolled 25 patients. Median plasma Cmax of dacomitinib in Cycle 1 Day 10 was 83.40ng/mL. Average median plasma dacomitinib concentration during the 4-day dose interruption was 42.63ng/mL. In the first 8 weeks of treatment 1) 80% of patients used concomitant medications for dermatologic AEs, 76% for diarrhea, and 44% for stomatitis, and 2) all patients experienced treatment-emergent AEs and 28% had all-causality Grade 3 AEs. CONCLUSION: At 45mg QD dosing, PK parameters of plasma dacomitinib in Cycle 1 Day 10 were comparable to that obtained in Cycle 1 Day 14 from other dacomitinib studies. Average median plasma dacomitinib concentration during the 4-day dose interruption was approximately half of the median plasma Cmax of dacomitinib observed prior to dose interruption. The toxicity profile was consistent with that from other studies of dacomitinib.
Authors: P J Stiff; H Erder; W I Bensinger; C Emmanouilides; T Gentile; J Isitt; Z J Lu; R Spielberger Journal: Bone Marrow Transplant Date: 2006-02 Impact factor: 5.483
Authors: Pasi A Jänne; David S Boss; D Ross Camidge; Carolyn D Britten; Jeffrey A Engelman; Edward B Garon; Feng Guo; Steven Wong; Jane Liang; Stephen Letrent; Robert Millham; Ian Taylor; S Gail Eckhardt; Jan H M Schellens Journal: Clin Cancer Res Date: 2011-01-10 Impact factor: 12.531
Authors: Pasi A Jänne; Sai-Hong I Ou; Dong-Wan Kim; Geoffrey R Oxnard; Renato Martins; Mark G Kris; Frank Dunphy; Makoto Nishio; Joseph O'Connell; Cloud Paweletz; Ian Taylor; Hui Zhang; Zelanna Goldberg; Tony Mok Journal: Lancet Oncol Date: 2014-11-05 Impact factor: 41.316
Authors: Suresh S Ramalingam; Pasi A Jänne; Tony Mok; Kenneth O'Byrne; Michael J Boyer; Joachim Von Pawel; Adam Pluzanski; Mikhail Shtivelband; Lara Iglesias Docampo; Jaafar Bennouna; Hui Zhang; Jane Q Liang; Jim P Doherty; Ian Taylor; Cecile B Mather; Zelanna Goldberg; Joseph O'Connell; Luis Paz-Ares Journal: Lancet Oncol Date: 2014-10-15 Impact factor: 41.316
Authors: Suresh S Ramalingam; Fiona Blackhall; Maciej Krzakowski; Carlos H Barrios; Keunchil Park; Isabel Bover; Dae Seog Heo; Rafael Rosell; Denis C Talbot; Richard Frank; Stephen P Letrent; Ana Ruiz-Garcia; Ian Taylor; Jane Q Liang; Alicyn K Campbell; Joseph O'Connell; Michael Boyer Journal: J Clin Oncol Date: 2012-07-02 Impact factor: 44.544